Friday, 06 January 2017 21:46

Anticoagulation news items. Weeks commencing 3rd January 2017

Thrombolysis for acute deep vein thrombosis

Cochrane Database of Systematic Reviews

Evidence suggests that systemic administration and catheter-directed thrombolysis have similar effectiveness. Strict eligibility criteria may be necessary to reduce the risk of bleeding complications, but may limit the applicability of this treatment.


Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors

American Journal of Cardiology

Findings from large, population-based study in US suggest being treated with CYP2C19-inhibiting SSRI (fluoxetine/fluvoxamine) when initiating clopidogrel
may be linked to increased risk of ischaemic events (HR 1.12; 95% CI, 1.01-1.24) vs. those treated with noninhibiting SSRI.


Impact of self-funding on patient experience of oral anticoagulation self-monitoring: a qualitative study

BMJ Open

Analysis of 26 interviews noted variable provision of self-monitoring equipment caused resentment and there were worries about cost of test strips. However,
self-funding did mean that interviewees felt a sense of ownership and were determined to persevere to overcome problems.


Revised SPC: Sustanon 250, 250mg/ml solution for injection (testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, testosterone decanoate)

electronic Medicines Compendium

Section 4.4 now advises that testosterone should be used with caution in patients with thrombophilia, as there have been post-marketing studies and reports of thrombotic events in these patients during testosterone therapy.


US FDA and European Medicines Agency (EMA) accept for a review, a marketing authorisation application for betrixaban

Biospace Inc.

Betrixaban is an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism (VTE) in acute
medically ill patients with risk factors for VTE. The application is based on data from the phase III APEX study.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: